webinar register page

Webinar banner
ISE Webinar: Low-Risk Thyroid Cancer in Adults: Update on Management
Most patients with differentiated thyroid cancer fall into low risk stages, where survival is >90%. Therefore, for these patients, initial stratification for structural disease risk for recurrence should be the primary determinant for therapeutic decision-making about surgery, radioiodine, and TSH suppression.
After primary therapy, surveillance data from serum thyroglobulin testing and ultrasound imaging can be used to guide long-term follow-up.

After this session, you will be given the tools to:
• Recognize how to determine risks for both structural recurrence and disease-specific mortality based upon initial staging of patients with differentiated thyroid cancer.

• Apply evidence-based recommendations to decision making about extent of surgery, I131 therapy and TSH suppression.

• Utilize results from surveillance imaging and thyroglobulin testing to determine long-term follow-up strategies.
Webinar logo
* Required information
Loading

Speakers

Susan J. Mandel (Speaker)
M.D., M.P.H.; Professor of Medicine and Radiology, Chief of the Division of Endocrinology, Diabetes and Metabolism @University of Pennsylvania
After medical school at the College of Physicians and Surgeons, Susan Mandel completed a medical residency at Columbia Presbyterian Medical Center and a fellowship in endocrinology at the Brigham and Women’s. At Penn, she oversees a clinical practice with over 23,000 annual visits. Her clinical practice focuses on patients with thyroid neoplasia and she has been recognized for clinical excellence with the Penn Duhring Clinical Specialist award. Her research interests include the use of sonography in the evaluation of patients with thyroid nodules and cancer, and thyroid disease during pregnancy. Dr. Mandel has served on the writing groups for the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and the Management of Thyroid Disease during Pregnancy.
Cosimo Durante (Chair)
M.D., Ph.D @Sapienza University of Rome
Cosimo Durante is Associate Professor of Internal Medicine at the University of Rome Sapienza, Rome, Italy, where he received his MD and residency/PhD training in Endocrinology and Metabolism. His research interests are focused on thyroid tumors management, including both benign and malignant neoplasms. He has demonstrated record of successful and productive research projects to more personalized thyroid nodule and thyroid cancer follow-up strategies.